Trials / Completed
CompletedNCT02366676
Efficacy of IARULIL® in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract
Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract: a Multicenter, Prospective Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 105 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- Female
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract
Detailed description
The purpose of this study is to evaluate the efficacy of combined intravesical therapy with hyaluronic acid and chondroitin sulphate(IARULIL®) in the treatment of recurrent cystitis refractory to oral Escherichia Coli extract(Uro-Vaxom®) and the change of urinary tract infection symptoms after intravesical instillation treatment with IARULIL®.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hyaluronic acid and chondroitin sulphate | IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd\~5th month:once a month) |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2018-01-01
- Completion
- 2019-10-30
- First posted
- 2015-02-19
- Last updated
- 2019-12-02
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02366676. Inclusion in this directory is not an endorsement.